4G6K
Crystal structure of the therapeutic antibody binding fragment of gevokizumab in its unbound state
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | SLS BEAMLINE X06SA |
Synchrotron site | SLS |
Beamline | X06SA |
Temperature [K] | 100 |
Detector technology | PIXEL |
Collection date | 2011-11-22 |
Detector | PSI PILATUS 6M |
Wavelength(s) | 0.91 |
Spacegroup name | P 21 21 21 |
Unit cell lengths | 74.345, 75.092, 88.862 |
Unit cell angles | 90.00, 90.00, 90.00 |
Refinement procedure
Resolution | 27.750 - 1.900 |
R-factor | 0.184 |
Rwork | 0.183 |
R-free | 0.21080 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | 1PZ5 and 3BKJ |
RMSD bond length | 0.007 |
RMSD bond angle | 1.030 |
Data reduction software | XDS |
Data scaling software | XDS |
Phasing software | PHASER |
Refinement software | BUSTER (2.11.2) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 57.400 | |
High resolution limit [Å] | 1.900 | 1.900 |
Rmerge | 0.076 | |
Number of reflections | 41364 | |
<I/σ(I)> | 19.4 | |
Completeness [%] | 100.0 | |
Redundancy | 6.5 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, SITTING DROP | 5 | 293 | 14.3% w/v PEG 3350 and 0.14M tri-sodium citrate at pH 5.0 equilibrated against 24% w/v PEG 3350, VAPOR DIFFUSION, SITTING DROP, temperature 293K |